Drug Profile
Crobenetine
Alternative Names: BIII-890; BIII-890-CLLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-ischaemics; Benzomorphans; Neuroprotectants; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Stroke
Most Recent Events
- 17 Apr 2009 Discontinued - Phase-II for Stroke in Germany and Spain (IV)
- 17 Apr 2009 Discontinued - Preclinical for Pain in Germany (IV)
- 08 Aug 2003 This compound is still in active development